drugset / Trial / NCT00394095

Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine

NCT00394095

RandomizedFactorialTriple-blindTreatment

Summary

The primary objective of this study is to examine the efficacy of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder. The secondary objective is to examine the tolerability of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.

Timeline

Start
2006-12
Primary completion
2009-08
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 300 mg Oral
Subject Topiramate Small molecule 400 mg Oral

Indications